Studies on the Metabolic Fate of Amrubicin Hydrochloride(SM-5887), a Novel Antitumor Agent (8)-Drug-drug Interactions of SM-5887 in Protein Binding.
|
Accession number;99A0241104
|
| Title;Studies on the Metabolic Fate of Amrubicin Hydrochloride(SM-5887), a Novel Antitumor Agent (8)-Drug-drug Interactions of SM-5887 in Protein Binding. |
| Author;
NAKAI SHUNJI
(Sumitomo Chemical Co., Ltd.)
ITO MASAKI
(Sumitomo Chemical Co., Ltd.)
KANAMARU HIROSHI
(Sumitomo Chemical Co., Ltd.)
NAKATSUKA IWAO
(Sumitomo Chemical Co., Ltd.)
|
Journal Title;Japanese Pharmacology & Therapeutics
|
Journal Code:Z0947A
|
ISSN:0386-3603
|
|
VOL.27;NO.Suppl.1;PAGE.S.551-S.556(1999)
|
| Figure&Table&Reference;FIG.2, TBL.2, REF.6 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;In vitro protein binding of amrubicin hydrochloride(SM-5887), a novel antitumor agent, and some drugs(indomethacin, vincristine and cisplatin) which might be clinically co-administrated with SM-5887, was investigated in order to evaluate the drug interaction of SM-5887 with them. 1) As for protein binding ratios of SM-5887, although a slight or significant changes were observed in the presence of indomethacin, vincristine or cisplatin, they did not seem to affect the pharmacokinetic profile of SM-5887. 2) Protein binding ratios of indomethacin were not significantly affected by the coexistence of SM-5887. As for protein binding ratios of vincristine or cisplatin, although they were slightly or significantly changed by the presence of SM-5887, these changes seemed to have little influence on the pharmacokinetic profile of vincristine or cisplatin. (author abst.) |
|
|
|
Related Articles;
|
|
